Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Race Oncology Ltd has announced a significant breakthrough in its intellectual property with the discovery and patent filing of three photoisomers of bisantrene, which have different biological and anticancer activities. This advancement is expected to provide 20 years of protection for the active pharmaceutical ingredient of RC220, potentially enhancing the company’s commercial prospects. Additionally, the company is progressing with its Phase 1 clinical trial of RC220, having safely treated two patients, and is expanding its trial sites in Hong Kong and South Korea. These developments, coupled with strong financial management and additional funding from shareholders, position Race Oncology favorably for future growth and innovation in cancer treatment.
More about Race Oncology Ltd.
Race Oncology Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of cancer therapies. The company’s primary product is bisantrene, a drug with anticancer properties, which is being advanced through clinical trials for various cancer treatments.
Average Trading Volume: 496,171
Technical Sentiment Signal: Buy
Current Market Cap: A$605.9M
For detailed information about RAC stock, go to TipRanks’ Stock Analysis page.